File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: CDK4/6 inhibitor plus endocrine therapy for hormone receptor-positive, HER2-negative metastatic breast cancer: The new standard of care

TitleCDK4/6 inhibitor plus endocrine therapy for hormone receptor-positive, HER2-negative metastatic breast cancer: The new standard of care
Authors
KeywordsCDK4/6 inhibitor
endocrine therapy
HER2-negative
hormone receptor-positive
metastatic breast cancer
overall survival
progression-free survival
quality of life
Issue Date2021
Citation
Asia-Pacific Journal of Clinical Oncology, 2021, v. 17, n. S1, p. 3-14 How to Cite?
AbstractPatients presenting with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2–) metastatic breast cancer (MBC) are usually treated with endocrine therapy (ET), except if there is a concern about endocrine resistance or a need to achieve rapid disease control due to visceral crisis. The combination of CDK4/6 inhibitor + ET has now replaced single-agent ET as the standard first-line treatment; and it can also be considered a standard option in the second-line setting. This review briefly summarizes recently reported efficacy findings from the key phase III clinical trials of CDK4/6 inhibitor + ET in patients with HR+/HER2– MBC, including evidence that adding a CDK4/6 inhibitor to ET improves overall survival and does so without reducing patients’ quality of life. There is still much to learn regarding the use of CDK4/6 inhibitors and how they may be optimally integrated into clinical practice. In particular, there is a need for specific biomarkers that help predict the likelihood of response or resistance to CDK4/6 inhibitor therapy; and for data to guide treatment decisions when a patient's disease progresses on a CDK4/6 inhibitor.
Persistent Identifierhttp://hdl.handle.net/10722/326502
ISSN
2023 Impact Factor: 1.4
2023 SCImago Journal Rankings: 0.531
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorHui, Rina-
dc.contributor.authorde Boer, Richard-
dc.contributor.authorLim, Elgene-
dc.contributor.authorYeo, Belinda-
dc.contributor.authorLynch, Jodi-
dc.date.accessioned2023-03-10T02:19:44Z-
dc.date.available2023-03-10T02:19:44Z-
dc.date.issued2021-
dc.identifier.citationAsia-Pacific Journal of Clinical Oncology, 2021, v. 17, n. S1, p. 3-14-
dc.identifier.issn1743-7555-
dc.identifier.urihttp://hdl.handle.net/10722/326502-
dc.description.abstractPatients presenting with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2–) metastatic breast cancer (MBC) are usually treated with endocrine therapy (ET), except if there is a concern about endocrine resistance or a need to achieve rapid disease control due to visceral crisis. The combination of CDK4/6 inhibitor + ET has now replaced single-agent ET as the standard first-line treatment; and it can also be considered a standard option in the second-line setting. This review briefly summarizes recently reported efficacy findings from the key phase III clinical trials of CDK4/6 inhibitor + ET in patients with HR+/HER2– MBC, including evidence that adding a CDK4/6 inhibitor to ET improves overall survival and does so without reducing patients’ quality of life. There is still much to learn regarding the use of CDK4/6 inhibitors and how they may be optimally integrated into clinical practice. In particular, there is a need for specific biomarkers that help predict the likelihood of response or resistance to CDK4/6 inhibitor therapy; and for data to guide treatment decisions when a patient's disease progresses on a CDK4/6 inhibitor.-
dc.languageeng-
dc.relation.ispartofAsia-Pacific Journal of Clinical Oncology-
dc.subjectCDK4/6 inhibitor-
dc.subjectendocrine therapy-
dc.subjectHER2-negative-
dc.subjecthormone receptor-positive-
dc.subjectmetastatic breast cancer-
dc.subjectoverall survival-
dc.subjectprogression-free survival-
dc.subjectquality of life-
dc.titleCDK4/6 inhibitor plus endocrine therapy for hormone receptor-positive, HER2-negative metastatic breast cancer: The new standard of care-
dc.typeArticle-
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.doi10.1111/ajco.13555-
dc.identifier.pmid33506626-
dc.identifier.scopuseid_2-s2.0-85099810000-
dc.identifier.volume17-
dc.identifier.issueS1-
dc.identifier.spage3-
dc.identifier.epage14-
dc.identifier.eissn1743-7563-
dc.identifier.isiWOS:000613762100001-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats